Pure Bioscience (PURE) 1.1900 $PURE PURE Bioscience

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pure Bioscience (PURE) 1.1900 $PURE

PURE Bioscience Reports Fiscal Second Quarter 2014 Financial Results
Marketwire - Thu Mar 13, 3:02PM CDT
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the second fiscal quarter ended January 31, 2014.

PURE Bioscience Hosts Q2 Results Conference Call March 13th, 2014 and Reviews Progress of SDC-Based Food Safety Solutions Strategy
Marketwire - Mon Mar 03, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that the Company will host an investor conference call on Thursday, March 13th, 2014 at 1:30pm PDT (4:30pm EDT).

PURE Bioscience Business Update and Goals -- Food Safety Strategy Gaining Traction
Marketwire - Thu Jan 30, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, announced that execution of its Food Safety Solutions Strategy continues to progress. The Company also announced its goals for calendar year 2014.

PURE Developing SDC-Based Antimicrobial for Direct Food Application
Marketwire - Tue Jan 28, 7:31AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced progress in development of a SDC-based antimicrobial for direct food contact. The Company is testing formulations to be used as a rinse or processing aid on produce, poultry, and meats.

PURE Completes Phase One Technology Transfer for Expanded Production -- Intercon SDC Facility Online
Marketwire - Thu Jan 23, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced it has completed the first phase of the SDC technology transfer to its collaboration partner, Intercon Chemical Company (ICC). The first phase consists of the partial transfer of PURE's unique and proprietary SDC manufacturing process into a new and dedicated production facility at ICC's St. Louis manufacturing location.

PURE's SDC-Based Food Safety Solutions Strategy Gains Traction -- Initial Orders From Three Food Processors
Marketwire - Thu Jan 16, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced continued progress on its strategic positioning as a food safety solution which was launched this past Fall.

5W Public Relations Expands Corporate Practice, Adds PURE Bioscience, Inc. to Client Roster
PR Newswire - Wed Dec 18, 7:45AM CST
5W Public Relations, one of the 25 largest independent public relations firms in the U.S., announced the addition of PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial agent, to its diverse roster of corporate clients.

PURE Bioscience Reports Fiscal First Quarter 2014 Financial Results
Marketwire - Thu Dec 12, 3:05PM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2013 (Fiscal Q1 2014).

PURE Announces Strategic Collaboration With Intercon Chemical Company
Marketwire - Thu Dec 12, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced it has entered into a five-year strategic collaboration agreement with St. Louis-based Intercon Chemical Company (ICC). The agreement consists of a multi-pronged approach to accelerate the commercialization of PURE's unique and proprietary SDC-based products.

PURE Bioscience Hosts Q1 Results Conference Call December 12, 2013
Marketwire - Mon Dec 09, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that the Company will host an investor conference call on Thursday, December 12, 2013 at 2:00 PM Pacific Time (5:00 pm Eastern Time).

PURE Announces Distribution Agreement With Brenntag Specialties, Inc.
Marketwire - Mon Dec 02, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced it has entered into a three-year distribution agreement with Brenntag Specialities, Inc. ("Brenntag"). The non-exclusive agreement provides Brenntag the worldwide rights to distribute PURE's unique and proprietary SDC-based antimicrobial SILVERION(R) 2400 as an active ingredient or preservative for use in personal care products.

PURE Bioscience to Present at 6th Annual LD MICRO Conference
Marketwire - Mon Nov 25, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that Peter C. Wulff, CFO & COO, will present at the Sixth Annual LD MICRO Conference on Thursday, December 5th, at 1:00 PST, at the Luxe Hotel Sunset Boulevard in Los Angeles.

PURE Bioscience Reports Fiscal 2013 Year End Financial Results
Marketwire - Thu Oct 24, 3:05PM CDT
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2013 ("Fiscal 2013").

PURE Bioscience to Host Year End Results Conference Call October 24, 2013
Marketwire - Tue Oct 22, 7:30AM CDT
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that the Company will host an investor conference call on Thursday, October 24, 2013 at 2:00 PM Pacific Time (5:00 pm Eastern Time). In addition to reviewing fiscal year end 2013 financial results, the purpose of this call is to:

PURE Bioscience names William Otis as sixth board member
M2 - Wed Oct 09, 5:12AM CDT
Antimicrobial company PURE Bioscience (OTCQBURE) revealed on Tuesday the appointment of William Otis to its board of directors.

PURE Bioscience Appoints Sixth New Board Member
Marketwire - Tue Oct 08, 7:30AM CDT
PURE Bioscience (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced the appointment of William Otis to its Board of Directors. Mr. Otis is the sixth member to join the Company's Board of Directors.

PURE Bioscience Appoints New CEO
Marketwire - Tue Sep 10, 7:30AM CDT
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced the appointment of Hank Lambert as its new Chief Executive Officer. Mr. Lambert replaces the interim CEO, Dave Pfanzelter, who remains as Chairman of the Board. The company reported that the management change is part of its previously announced reorganization establishing new and experienced leadership focused on commercialization of SDC technology in the food industry as a unique and proprietary antimicrobial agent to protect consumer safety against various pathogens.

PURE Bioscience expands sales and marketing team with addition of Cliff Wechsler & Tom Myers
M2 - Thu Aug 29, 4:35AM CDT
Antimicrobial company PURE Bioscience (OTCQBURE) said on Wednesday that it is strengthening of its sales and marketing leadership team to drive the commercialisation of SDC technology to protect consumer safety against various pathogens in the food industry.

PURE Bioscience Strengthens Sales and Marketing Organization
Marketwire - Wed Aug 28, 7:30AM CDT
PURE Bioscience (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced the strengthening of its sales and marketing leadership team. The company appointed Cliff Wechsler as its new Executive Vice President of Sales, and Tom Myers assumed the position of Executive Vice President of Marketing and Product Development. The company reported that the management change established the leadership to drive the commercialization of SDC technology in the food industry as a novel and proprietary antimicrobial agent to protect consumer safety against various pathogens.

Delisting of Securities of SmartHeat Inc., Ampal-American Israel Corporation, PURE Bioscience, Inc., Urologix, Inc. and Strategic Diagnostics Inc. From The NASDAQ Stock Market
GlobeNewswire - Mon Aug 19, 3:05PM CDT
The NASDAQ Stock Market announced today that it will delist the common stock of SmartHeat Inc. SmartHeat Inc.'s stock was suspended on November 09, 2012 and has not traded on NASDAQ since that time.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 185

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 198

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 136

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 112

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 184

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 158

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 149

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 0

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 138

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading

Top 5 Most Recently Viewed Articles

Analysts Raise Price Targets for Agilent After Strong Earnings

Updated Category News Views 139

Agilent Technologies Inc Reports Impressive Fourth Quarter Results Agilent Technologies Inc (NYSE: A) celebrated a positive earnings surprise for its latest quarterly results, significantly surpassing forecasts and setting a promising tone for the year ahead. The company's earnings per share reached $1.59, edging out analyst expectations, which were set at $1.58 per...

Continue Reading
AstraZeneca's Historic NYSE Move Signals Market Shift

Updated Category News Views 53

AstraZeneca's Gigantic Leap In the hustle of Wall Street's whirring machine, June 5, 2026, dawned with a palpable buzz. Why? AstraZeneca (NYSE:AZN) just pulled off the biggest market cap transfer in the New York Stock Exchange's epic 234-year saga. Now that's a splash, not just a ripple. It’s like watching a giant whale breach in an already crowded ocean. But what does...

Continue Reading
Doughlicious Brings Irresistible Frozen Treats to Target Stores

Updated Category News Views 247

Doughlicious Expands Offerings into Target Stores Doughlicious, the celebrated brand born in London, is making waves across the United States as it announces its expansion into Target stores nationwide. Building on their successful U.S. launch at Whole Foods Market, the brand is excited to bring its crave-worthy frozen cookie dough and gelato bites to an even broader...

Continue Reading
Amber Grid Seeks New CEO: Selection Process Announced

Updated Category News Views 246

Amber Grid CEO Selection Process Initiated AB Amber Grid, with the legal entity code: 303090867, is located at Laisv?s ave. 10, LT-04215 Vilnius, Lithuania. As the current CEO's five-year tenure approaches its conclusion, the Board has officially announced the commencement of the selection process for the next CEO. Application Timeline and Processes Interested candidates...

Continue Reading
Vishay Precision Group Reports Third Quarter Results for FY24

Updated Category News Views 117

Vishay Precision Group Announces Q3 2024 Financial Results Vishay Precision Group, Inc. (NYSE: VPG), a recognized leader in precision measurement and sensing technologies, recently released its financial results for the third quarter of fiscal 2024, closing on September 28, 2024. The report highlights various metrics that provide insight into the company’s performance...

Continue Reading